{"id":"lapaquistat-acetate-and-ezetimibe","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal effects (diarrhea, constipation)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Muscle-related symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lapaquistat acetate is an ACAT2 inhibitor that reduces cholesterol esterification in the intestine, decreasing cholesterol absorption. Ezetimibe is an NPC1L1 inhibitor that blocks cholesterol uptake at the intestinal brush border. The combination targets complementary pathways in intestinal cholesterol homeostasis to achieve additive LDL-lowering effects.","oneSentence":"Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while ezetimibe blocks NPC1L1 to further decrease cholesterol uptake, together lowering LDL cholesterol.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:26.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia / elevated LDL cholesterol"}]},"trialDetails":[{"nctId":"NCT00268697","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-10","conditions":"Hypercholesterolemia","enrollment":1267}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TAK-475","Zetia"],"phase":"phase_3","status":"active","brandName":"Lapaquistat acetate and ezetimibe","genericName":"Lapaquistat acetate and ezetimibe","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while ezetimibe blocks NPC1L1 to further decrease cholesterol uptake, together lowering LDL cholesterol. Used for Hypercholesterolemia / elevated LDL cholesterol.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}